[go: up one dir, main page]

WO2007015270A3 - Nouvelles compositions a liberation controlee a base d'inhibiteurs selectifs de la recapture de la serotonine - Google Patents

Nouvelles compositions a liberation controlee a base d'inhibiteurs selectifs de la recapture de la serotonine Download PDF

Info

Publication number
WO2007015270A3
WO2007015270A3 PCT/IN2006/000274 IN2006000274W WO2007015270A3 WO 2007015270 A3 WO2007015270 A3 WO 2007015270A3 IN 2006000274 W IN2006000274 W IN 2006000274W WO 2007015270 A3 WO2007015270 A3 WO 2007015270A3
Authority
WO
WIPO (PCT)
Prior art keywords
controlled release
composition
active
serotonin reuptake
released
Prior art date
Application number
PCT/IN2006/000274
Other languages
English (en)
Other versions
WO2007015270A2 (fr
Inventor
Avinash K Velhal
Vineeth Raghavan
Suryakumar Jayanthi
Himadri Sen
Original Assignee
Lupin Ltd
Avinash K Velhal
Vineeth Raghavan
Suryakumar Jayanthi
Himadri Sen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd, Avinash K Velhal, Vineeth Raghavan, Suryakumar Jayanthi, Himadri Sen filed Critical Lupin Ltd
Priority to JP2008524679A priority Critical patent/JP5153629B2/ja
Priority to AU2006274565A priority patent/AU2006274565B2/en
Publication of WO2007015270A2 publication Critical patent/WO2007015270A2/fr
Publication of WO2007015270A3 publication Critical patent/WO2007015270A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition pharmaceutique à libération contrôlée à base d'un inhibiteur sélectif de la recapture de la sérotonine. Cette composition comprend principalement un noyau contenant le principe actif, un ou plusieurs polymères à libération contrôlée et un ou plusieurs excipients de qualité pharmaceutique. La composition comporte éventuellement une revêtement à base d'un ou plusieurs polymères à libération contrôlée. La composition est préparée selon un procédé consistant à mélanger le principe actif avec un ou plusieurs polymères à libération contrôlée et un ou plusieurs excipients de qualité pharmaceutique. Ensuite, le mélange est soumis à une granulation, séché, lubrifié et transformé en comprimés. La composition est utilisée dans la fabrication d'un médicament, pour le traitement et/ou la prévention de troubles. Le principe actif est libéré en 2 à 8 heures environ, 10 à 25 % environ du principe actif étant libéré in vitro en 2 heures dans une solution de HCl 0,1N, selon une étude de dissolution menée avec 750 ml d'un milieu de dissolution, un testeur de dissolution USP et un agitateur à ailettes à 150 tours/minute. Environ 20 à 55 %, 50 à 75 % et 70 à 95 % du principe actif est libéré in vitro en 4, 6 et 8 heures, respectivement, dans un tampon Tris à pH 7,5, selon une étude de dissolution menée avec 1000 ml d'un milieu de dissolution, un testeur de dissolution USP et un agitateur à ailettes à 150 tours/minute.
PCT/IN2006/000274 2005-08-02 2006-08-01 Nouvelles compositions a liberation controlee a base d'inhibiteurs selectifs de la recapture de la serotonine WO2007015270A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2008524679A JP5153629B2 (ja) 2005-08-02 2006-08-01 選択的セロトニン再取り込み阻害剤の新規の制御放出組成物
AU2006274565A AU2006274565B2 (en) 2005-08-02 2006-08-01 Novel controlled release compositions of selective serotonin reuptake inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN696/KOL/2005 2005-08-02
IN696KO2005 2005-08-02

Publications (2)

Publication Number Publication Date
WO2007015270A2 WO2007015270A2 (fr) 2007-02-08
WO2007015270A3 true WO2007015270A3 (fr) 2007-04-19

Family

ID=37392535

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000274 WO2007015270A2 (fr) 2005-08-02 2006-08-01 Nouvelles compositions a liberation controlee a base d'inhibiteurs selectifs de la recapture de la serotonine

Country Status (3)

Country Link
JP (1) JP5153629B2 (fr)
AU (1) AU2006274565B2 (fr)
WO (1) WO2007015270A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2727915B1 (fr) 2007-09-13 2016-04-13 Concert Pharmaceuticals Inc. Synthèse de catéchols deutériés et benzo[d] [1,3]dioxoles et leurs dérivés
CA2769872A1 (fr) * 2009-08-24 2011-03-03 H. Lundbeck A/S Nouvelles compositions de 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
WO2012123922A1 (fr) 2011-03-17 2012-09-20 Lupin Limited Compositions pharmaceutiques à libération contrôlée d'un inhibiteur sélectif de la recapture de sérotonine
KR102441089B1 (ko) * 2020-06-15 2022-09-07 환인제약 주식회사 의약 조성물
CN112494445A (zh) * 2020-12-11 2021-03-16 丽珠集团丽珠制药厂 一种马来酸氟伏沙明组合物及其制备方法
CN117503741A (zh) * 2023-11-06 2024-02-06 苏州盛达药业有限公司 一种缓释型氟伏沙明及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003670A1 (fr) * 1995-07-20 1997-02-06 Smithkline Beecham P.L.C. Compositions de paroxetine a liberation controlee
WO1999000131A1 (fr) * 1997-06-30 1999-01-07 Endo Pharmaceuticals Inc. Nouveau procede de fabrication de dispersions solides de paroxetine
WO1999056751A1 (fr) * 1998-05-07 1999-11-11 Endo Pharmaceuticals Inc. Procede de production en phase aqueuse de dispersions solides de paroxetine
WO2002069969A1 (fr) * 2001-03-02 2002-09-12 A/S Gea Farmaceutisk Fabrik Procede de preparation de comprimes pharmaceutiques contenant un hydrochlorure anhydre de paroxetine
WO2004058229A1 (fr) * 2002-12-24 2004-07-15 Biovail Laboratories Inc. Formulations d'inhibiteurs selectifs de recapture de la serotonine a liberation modifiee

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
DE60042352D1 (de) * 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
AU782059B2 (en) * 1999-05-20 2005-06-30 Elan Pharma International Limited Multiparticulate controlled release selective serotonin reuptake inhibitor formulations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003670A1 (fr) * 1995-07-20 1997-02-06 Smithkline Beecham P.L.C. Compositions de paroxetine a liberation controlee
WO1999000131A1 (fr) * 1997-06-30 1999-01-07 Endo Pharmaceuticals Inc. Nouveau procede de fabrication de dispersions solides de paroxetine
WO1999056751A1 (fr) * 1998-05-07 1999-11-11 Endo Pharmaceuticals Inc. Procede de production en phase aqueuse de dispersions solides de paroxetine
WO2002069969A1 (fr) * 2001-03-02 2002-09-12 A/S Gea Farmaceutisk Fabrik Procede de preparation de comprimes pharmaceutiques contenant un hydrochlorure anhydre de paroxetine
WO2004058229A1 (fr) * 2002-12-24 2004-07-15 Biovail Laboratories Inc. Formulations d'inhibiteurs selectifs de recapture de la serotonine a liberation modifiee

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DOUGHTY D G ET AL: "Dry Formulation Process Improves Stability of Paroxetine Tablets - Useful in the Treatment of Depression, Neuroses, Etc", STN WPIDS, 22 June 1995 (1995-06-22), XP002913188 *

Also Published As

Publication number Publication date
JP5153629B2 (ja) 2013-02-27
AU2006274565A1 (en) 2007-02-08
JP2009503057A (ja) 2009-01-29
AU2006274565B2 (en) 2012-05-17
WO2007015270A2 (fr) 2007-02-08

Similar Documents

Publication Publication Date Title
WO2003072025A3 (fr) Formulations a liberation modifiee d'au moins une forme de tramadol
WO2007000778A3 (fr) Compositions pharmaceutiques a liberation modifiee et leurs procedes
WO2001078725A3 (fr) Formulations a liberation modifiee contenant un agent hypnotique
WO2001085257A3 (fr) Compositions d'antagoniste opioide et formes de dosage
WO2007015270A3 (fr) Nouvelles compositions a liberation controlee a base d'inhibiteurs selectifs de la recapture de la serotonine
AU703242B2 (en) Film coated tablet of paracetamol and domperidone
WO2004026256A3 (fr) Preparations d'opioides a liberation soutenue et methodes d'utilisation
WO2007010559A3 (fr) Nouvelle composition de forme dosifiee pharmaceutique a liberation modifiee comprenant un inhibiteur de l'enzyme cyclooxygenase
WO2008084698A1 (fr) Composition pharmaceutique à libération entretenue de tacrolimus
Tuite et al. Recent developments in the pharmacological treatment of Parkinson’s disease
TW200833376A (en) Sustained-release composition and method for producing the same
MX2012013135A (es) Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
WO2003005967A3 (fr) Formulation a liberation double comportant un ester ethylique de levodopa et un inhibiteur de decarboxylase dans une couche a liberation instantanee avec un ester ethylique de levodopa et un inhibiteur de decarboxylase dans un noyau a liberation controlee
CA2415154A1 (fr) Preparations a liberation modifiee contenant des inhibiteurs selectifs de la recapture de la serotonine
ATE253354T1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
DE60035579D1 (de) Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme
WO2006053089A3 (fr) Methodes et formulations permettant de preparer des compositions pharmaceutiques contenant du bupropion
JP2004522780A5 (fr)
ATE296632T1 (de) Molsidominhaltige oral anzuwendende verabreichungsform mit verzögerter wirkstoffabgabe
US20030229101A1 (en) Tablets comprising ciprofloxacin hydrochloride
WO2002017877A3 (fr) Compositions pour granules pharmaceutiques a liberation controlee destinees a limiter les effets secondaires de medicaments
ATE382332T1 (de) Formulierung mit kontrollierter freisetzung enthaltend tamsulosin hydrochlorid
TW200621314A (en) Methods and formulations for making pharmaceutical compositions containing bupropion

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008524679

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006274565

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006274565

Country of ref document: AU

Date of ref document: 20060801

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006274565

Country of ref document: AU

122 Ep: pct application non-entry in european phase

Ref document number: 06780554

Country of ref document: EP

Kind code of ref document: A2